US patent for Exco InTouch's mobile DNA technology

Exco InTouch has been granted a US patent corresponding to its mDNA automated management tool that identifies, distributes and manages patients and their mobile device interactivity in clinical and healthcare programmes.

mDNA provides study managers, sponsors and healthcare providers with effective control over the environment in which patients interact with mobile data capture services, thereby offering device management benefits for traditional, fully provisioned clinical trials.

In addition, by managing each patients’ interactions within defined parameters, mDNA overcomes the perceived barriers to the adoption of BYOD (Bring Your Own Device) in clinical trial and healthcare settings. Through its ability to identify the patient device in use and manage the system response accordingly, mDNA ensures consistency of display and content in a BYOD environment.

As well as these patient centered benefits, mDNA facilitates the remote maintenance and update of electronic clinical outcome assessments (eCOA) and electronic patient reported outcomes (ePRO) solutions. Furthermore, mDNA manages and protects personally identifiable information (PII), creating unique identifiers for each user and removing the requirement for PII to be stored within the system.

Tim Davis, CEO and founder of Exco InTouch commented: “Since its formation, Exco InTouch has been committed to the development of innovative mobile solutions to help support patients in clinical trials and general healthcare settings. We are excited by the addition of the US patent for our ground-breaking mDNA technology to our market leading patient engagement portfolio."